Updated on 2024/08/07

Information

 

写真a

 
MATSUO MIOKO
 
Organization
Kyushu University Hospital Otorhinolaryngology Head and Neck Surgery Assistant Professor
School of Medicine Department of Medicine(Joint Appointment)
Title
Assistant Professor
Contact information
メールアドレス
Tel
0926425668
Profile
耳鼻咽喉頭頸部外科全般を対象としていますが、中でも、頭頸部腫瘍と気道管理に関する研究が多くを占めています。
External link

Degree

  • Doctor of Philosophy No.2770

Research Interests・Research Keywords

  • Research theme:Examination of the treatment of head and neck cancer

    Keyword:head and neck cancer

    Research period: 2019.4 - 2031.4

Papers

  • Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab Invited Reviewed International journal

    MiokoMatsuo, Ryuji Yasumatsu, Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Kazuki Hashimoto, Masahiko Taur, Ryutaro Uchi, Takashi Nakagawa

    Oral Oncology   101   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 特集 頭頸部癌の術前・術後管理のコツ 術後 術後経過観察・フォローアップのコツ

    松尾 美央子

    JOHNS   40 ( 7 )   776 - 779   2024.7   ISSN:09106820

     More details

    Publisher:東京医学社  

    DOI: 10.24479/ohns.0000001155

    CiNii Research

  • Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation

    Matsuo, M; Masuda, M; Yamauchi, M; Hashimoto, K; Kogo, R; Sato, M; Masuda, S; Nakagawa, T

    CANCERS   16 ( 14 )   2024.7   ISSN:2072-6694 eISSN:2072-6694

     More details

    Language:English   Publisher:Cancers  

    The optimal timing for actively discontinuing immune checkpoint inhibitor therapy in long-term responders with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains unresolved. We conducted a retrospective study of 246 patients with R/M HNSCC treated with nivolumab to determine the optimal timing to actively discontinue nivolumab therapy. We examined the point at which progression-free survival (PFS) plateaued in all cases. We compared the prognosis of 19 (7.7%) ongoing cases and 227 (92.3%) discontinued cases and analyzed treatment duration and treatment-free interval (TFI). The 6-year overall survival was 11.8% (median, 12.1), and the 6-year PFS was 15.3% (median, 3.0). The PFS curve remained stable for 3 years. The median duration of nivolumab treatment was 2.9 months (range 0.03–81.9): Ongoing group, 41.8 (5.6–81.9); Decision group, 36.8 (4.0–70.1); Toxicity group, 30.6 (2.8–64.8); and progressive disease group, 2.0 (0.03–42.9). TFI in the Decision group was 15.1 months (0.6–61.6) and 30.6 months (2.8–64.8) in the Toxicity group. Long-term responses in R/M HNSCC patients treated with nivolumab are rare but gradually increasing. For this patient group, our best estimate of the optimal time to end treatment is 3 years, as the PFS in this study reached a plateau at that timepoint.

    DOI: 10.3390/cancers16142527

    Web of Science

    Scopus

    PubMed

  • 家族性大腸腺腫症に合併した甲状腺乳頭癌の2例

    犬塚 杏子, 次郎丸 梨那, 久我 亮介, 本郷 貴大, 古後 龍之介, 橋本 和樹, 松尾 美央子, 山元 英崇, 中川 尚志

    耳鼻と臨床   70 ( 3 )   150 - 155   2024.5   ISSN:0447-7227

     More details

    Language:Japanese   Publisher:耳鼻と臨床会  

  • Larynx-Preserving Reconstructive Surgeries for Cervical Esophageal Carcinoma -Current Status and Future Prospects-

    Kadota H., Yoshida S., Matsuo M., Yasumatsu R.

    Nihon Kikan Shokudoka Gakkai Kaiho   75 ( 2 )   102 - 102   2024.4   ISSN:00290645 eISSN:18806848

     More details

    Language:Japanese   Publisher:The Japan Broncho-esophagological Society  

    DOI: 10.2468/jbes.75.102

    CiNii Research

  • What in Essence is Gender Equality? -Career Advancement and Work-Life Balance-

    Matsuo M.

    Nihon Kikan Shokudoka Gakkai Kaiho   75 ( 2 )   106 - 106   2024.4   ISSN:00290645 eISSN:18806848

     More details

    Language:Japanese   Publisher:The Japan Broncho-esophagological Society  

    DOI: 10.2468/jbes.75.106

    CiNii Research

  • Risk Factors of Cetuximab-Induced Hypomagnesemia and the Effect of Magnesium Prophylaxis in Patients with Head and Neck Cancer: A Retrospective Study

    Matsukane Ryosuke, Isshiki Risa, Suetsugu Kimitaka, Minami Haruna, Hata Kojiro, Matsuo Mioko, Egashira Nobuaki, Hirota Takeshi, Nakagawa Takashi, Ieiri Ichiro

    Biological and Pharmaceutical Bulletin   47 ( 3 )   732 - 738   2024.3   ISSN:09186158 eISSN:13475215

     More details

    Language:English   Publisher:The Pharmaceutical Society of Japan  

    <p>Hypomagnesemia is a characteristic adverse event of cetuximab in patients with head and neck cancer (HNC). However, there is limited information about its prevalence, risk factors, and preventive strategies. This study aimed to investigate the risk factors of hypomagnesemia and examine the preventive effects of prophylactic magnesium (Mg) administration. We initially investigated HNC patients treated with cetuximab between 2013 and 2019. Our institute started prophylactic Mg treatment (20-mEq Mg sulfate administration before cetuximab) in practice during this period. We retrospectively assess the preventive efficacy by comparing patients before and after its implementation. In total, 109 patients were included. In 60 patients without prophylaxis, all-grade and grade ≥2 hypomagnesemia at 3 months occurred in 61.7 and 15.0% of patients. The incidence of hypomagnesemia was not affected by regimens and concomitant medications. In 49 patients treated with prophylactic Mg treatment, there was no significant decrease in the cumulative incidence of hypomagnesemia. However, the preventive Mg treatment eliminated the need for additional Mg repletion to maintain Mg levels in patients treated with paclitaxel + cetuximab. A risk factor in patients without prophylaxis was a low Mg level at pre-treatment (≤2.0 mg/dL) (odds ratio: 6.03, 95% confidence interval: 1.78–20.4, <i>p</i> = 0.004), whereas that in patients with prophylaxis was the number of cetuximab doses (≥10) (odds ratio: 5.50, 95% confidence interval: 1.52–19.87, <i>p</i> = 0.009). In conclusion, a low pre-treatment Mg level was the only risk factor that could be avoided by prophylactic Mg administration. This preventive intervention is recommended for managing cetuximab-induced hypomagnesemia.</p>

    DOI: 10.1248/bpb.b23-00714

    Scopus

    PubMed

    CiNii Research

  • 膵癌舌転移の1例

    宮崎 孝, 若崎 高裕, 次郎丸 梨那, 松尾 美央子, 中川 尚志

    口腔・咽頭科   37 ( 1 )   48 - 54   2024.3   ISSN:0917-5105

     More details

    Language:Japanese   Publisher:日本口腔・咽頭科学会  

    口腔領域の転移性悪性腫瘍は,全口腔悪性腫瘍の約1%で,中でも膵癌の舌転移は極めて稀とされる.今回,膵癌舌転移の1例を経験したので報告する.症例は56歳男性,主訴は舌痛,舌腫瘤.X年膵癌cT3N1aM0,StageIIBの診断で膵全摘術を施行.X+2年縦隔リンパ節再発を来し,緩和化学療法を開始した.PDによるレジメン変更及び縦隔病変への放射線治療により,病勢はコントロールできていた.X+4年,舌に疼痛を伴う腫瘤性病変が出現した.各種検査で膵癌舌転移と診断した.舌腫瘍は増大傾向で疼痛悪化に伴う経口摂取困難が生じていたため,緩和治療として舌部分切除術を施行した.舌痛は改善,経口摂取も良好となった.今回の外科治療は,がん終末期のQOL改善に寄与できた.(著者抄録)

  • Risk Factors of Cetuximab-Induced Hypomagnesemia and the Effect of Magnesium Prophylaxis in Patients with Head and Neck Cancer: A Retrospective Study(タイトル和訳中)

    Matsukane Ryosuke, Isshiki Risa, Suetsugu Kimitaka, Minami Haruna, Hata Kojiro, Matsuo Mioko, Egashira Nobuaki, Hirota Takeshi, Nakagawa Takashi, Ieiri Ichiro

    Biological & Pharmaceutical Bulletin   47 ( 3 )   732 - 738   2024.3   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

  • Risk Factors of Cetuximab-Induced Hypomagnesemia and the Effect of Magnesium Prophylaxis in Patients with Head and Neck Cancer: A Retrospective Study

    Matsukane, R; Isshiki, R; Suetsugu, K; Minami, H; Hata, K; Matsuo, M; Egashira, N; Hirota, T; Nakagawa, T; Ieiri, I

    BIOLOGICAL & PHARMACEUTICAL BULLETIN   47 ( 3 )   732 - 738   2024.3   ISSN:0918-6158 eISSN:1347-5215

  • Clinical Analysis of Oral Squamous Cell Carcinoma: A Single-institution Experience.

    Jiromaru R, Yasumatsu R, Matsuo M, Hashimoto K, Kogo R, Nakagawa T

    Cancer diagnosis & prognosis   4 ( 2 )   105 - 110   2024.3

     More details

    Language:English  

    DOI: 10.21873/cdp.10294

    PubMed

  • OK-432(ピシバニール)投与が奏功した再発性難治性舌根嚢胞の2例

    奥田 華英, 松尾 美央子, 古後 龍之介, 橋本 和樹, 佐藤 方宣, 京野 真理, 中川 尚志

    耳鼻と臨床   70 ( 1 )   20 - 25   2024.1   ISSN:0447-7227

     More details

    Language:Japanese   Publisher:耳鼻と臨床会  

    頭頸部領域には発生学的に病因の異なる嚢胞が生じることがあり、正中頸嚢胞、側頸嚢胞、リンパ管腫/奇形などの先天性嚢胞や、ガマ腫などの後天性嚢胞が挙げられる。これら嚢胞の治療法としては、手術摘出とOK-432(ピシバニール)に代表される硬化療法の2つに大別される。手術摘出や複数回の穿刺排液を繰り返すも難治性であった、咽頭に発生した嚢胞に対し、OK-432(ピシバニール)を投与し、効果を認めた2例を経験したので報告する。症例1は30代の女性で、舌根の嚢胞を2回切除するも数ヵ月で再増大した症例である。症例2は60代の女性で、30年以上にわたり舌根の嚢胞に手術処置を繰り返した症例である。2例ともOK-432(ピシバニール)投与で、縮小した状態が維持できるようになった。頭頸部領域に発生する嚢胞の中には、まれではあるが複数回再発し難治性のものもあり、この場合治療に難渋することとなる。外科的治療法で対応が困難な症例において、OK-432(ピシバニール)による硬化療法は、外来で対応可能な、かつ効果的な治療選択肢の一つとなり得ると思われた。(著者抄録)

  • A case of tongue metastasis of pancreatic cancer

    Miyazaki Takashi, Wakasaki Takahiro, Jiromaru Rina, Matsuo Mioko, Nakagawa Takashi

    Stomato-pharyngology   37 ( 1 )   48 - 54   2024   ISSN:09175105 eISSN:18844316

     More details

    Language:Japanese   Publisher:Japan Society of Stomato-pharyngology  

    Metastasis to the oral cavity accounts for about 1% of all oral malignancies. Among them, tongue metastasis of pancreatic cancer is considered to be extremely rare. We report a case of tongue metastasis of pancreatic cancer. The patient was a 56-year-old man with a chief complaint of tongue pain and a mass on the tongue. In year X, he underwent pancreatectomy for pancreatic cancer cT3N1aM0, Stage ⅡB. In year X+2, mediastinal lymph node recurrence occurred, and palliative chemotherapy was started. The patient underwent a regimen change due to PD and radiotherapy to the mediastinal lesion, and the disease was stable thereafter. In year X+4, a painful mass lesion appeared on the tongue. After several appropriate tests, he was diagnosed with tongue metastasis of pancreatic cancer. The tongue tumor tended to grow and worsening pain made oral intake difficult, so a partial tongue resection was performed as palliative treatment. As a result, the patient’s tumor-induced tongue pain and oral intake improved. This surgical treatment contributed to the improvement of QOL in the terminal stage of cancer.

    DOI: 10.14821/stomatopharyngology.37-048

    CiNii Research

  • 免疫チェックポイント阻害剤が奏功した口腔血管肉腫(Angiosarcoma:AS)の1例

    松尾 美央子

    耳鼻と臨床   69 ( 6 )   456 - 459   2023.11   ISSN:0447-7227

     More details

    Language:Japanese   Publisher:耳鼻と臨床会  

    症例は91歳女性で、右硬口蓋から歯肉にかけての腫瘤を主訴とした。CTで上顎骨破壊を伴う6cm大の腫瘤を認めたが、精査にて遠隔転移は認めなかった。腫瘍は1週間で急速に増大したため臨床的に悪性腫瘍と判断し、右上顎部分切除術と右頸部郭清術を施行し、病理所見で血管肉腫と診断した。術後20日目に切除創の一部に腫瘤病変が出現して1週間で急速に増大し、Combined Positive Scoreは100であったため、術後39日目よりPembrolizumab投与を開始した。最初は3週ごとに200mg/回を、その後は6週ごとに400mg/回を投与した。その結果、手術から6ヵ月経過して腫瘍はほぼ消失した状態を維持し、6週間ごとの投与を継続中である。有害事象は出現せず経過している。

  • Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan

    Tsuchihashi, K; Ito, M; Arita, S; Kusaba, H; Kusano, W; Matsumura, T; Kitazono, T; Ueno, S; Taguchi, R; Yoshihiro, T; Doi, Y; Arimizu, K; Ohmura, H; Kajitani, T; Nio, K; Nakano, M; Oshima, K; Tamura, S; Shirakawa, T; Shimokawa, H; Uchino, K; Hanamura, F; Okumura, Y; Komoda, M; Isobe, T; Ariyama, H; Esaki, T; Hashimoto, K; Komune, N; Matsuo, M; Matsumoto, K; Asai, K; Yoshitake, T; Yamamoto, H; Oda, Y; Akashi, K; Baba, E

    BMC CANCER   23 ( 1 )   1046   2023.10   eISSN:1471-2407

     More details

    Language:English   Publisher:BMC Cancer  

    Background: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy. Methods: We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy. Results: Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 – 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 – 25.8 months): 17.1 months (95%CI: 6.0 – not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 – 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months–NR): 40.8 months (95%CI: 12.1 – NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions. Conclusion: The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.

    DOI: 10.1186/s12885-023-11528-4

    Web of Science

    Scopus

    PubMed

  • 外切開法による甲状腺手術の際の合併症とその対策 Invited Reviewed International journal

    松尾 美央子

    頭頸部外科   2023.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Cholesterol granuloma of the anterior mediastinum: A case report and literature review

    Hongo, T; Jiromaru, R; Kuga, R; Matsuo, M; Oda, Y; Nakagawa, T

    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS   111   108852   2023.10   ISSN:2210-2612

     More details

    Language:English   Publisher:International Journal of Surgery Case Reports  

    Introduction: Cholesterol granulomas, which frequently present in the temporal bone of the skull, are recognized as benign lesions occurring due to chronic inflammation or hemorrhage. However, cholesterol granuloma of the mediastinum is extremely rare. Presentation of case: An asymptomatic 43-year-old man with an incidental finding of anterior mediastinal mass by positron emission tomography scan was referred to our hospital. Preoperative computed tomography showed a well-circumscribed nodule 2 cm in size in the anterior mediastinum. A total tumor resection through a suprasternal approach was performed. Microscopically, numerous cholesterol clefts with an alveolar-like growth pattern and foreign body reaction were observed, indicating a pathological diagnosis of cholesterol granuloma. Discussion: Cholesterol granuloma is generally thought to be initiated by cell degeneration and hemorrhage resulting from trauma or inflammation. The patient's long-term rugby experience may have played a role in the development of cholesterol granuloma. It is difficult to diagnose a cholesterol granuloma based on preoperative imaging alone, and anatomy often makes preoperative biopsy or cytology difficult. Conclusion: Complete resection and pathological examination may be unavoidable for diagnosis and treatment.

    DOI: 10.1016/j.ijscr.2023.108852

    Web of Science

    Scopus

    PubMed

  • Pembrolizumab Monotherapy Versus Pembrolizumab Plus Chemotherapy in Patients With Head and Neck Squamous Cell Carcinoma Reviewed International journal

    in vivo   37   2188 - 2196   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies Reviewed International journal

    Mioko Matsuoa, Kazuki Hashimoto, Ryunosuke Kogo, Rina Jiromaru, Takahiro Hongo, Tomomi Manako and Takashi Nakagawa

    in vivo   37   2147 - 2154   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies

    Matsuo, M; Hashimoto, K; Kogo, R; Jiromaru, R; Hongo, T; Manako, T; Nakagawa, T

    IN VIVO   37 ( 5 )   2147 - 2154   2023.9   ISSN:0258-851X eISSN:1791-7549

     More details

    Language:English   Publisher:In Vivo  

    Background/Aim: In recent years, individual patient cancer genomic profiling (CGP) has become more accessible, allowing determination of therapeutic strategies using driver gene mutations in cancer therapy. However, this precision oncology approach, tailored to specific patients, remains experimental. In this study, we verified the feasibility and benefit of using CGP to guide treatment of malignant head and neck tumors. We aimed to evaluate the profiling and clinical courses of patients with head and neck malignancies who underwent CGP and determine the extent to which CGP for head and neck malignancies has resulted in beneficial drug administration. Patients and Methods: We analyzed CGP results, prognosis, and drug administration status in 27 patients. These patients had completed (or were expected to complete) standard therapy or had rare cancers without standard therapy. Results: At least one somatic actionable gene alteration was seen in 25 (92.6%) patients, with a median number of actionable alterations per patient of 4 (range=0-11). Drugs in clinical trials were recommended to 22 (81.5%) patients, but none could participate. However, 3 patients (11.1%) could use approved drugs off-label based on CGP results. The most common genetic abnormality was TP53 (66.7%), with TP53 mutations leading to poor prognosis. Conclusion: CGP is clinically useful and serves as a bridge to increase the number of therapeutic options. However, candidate drugs confirmed using CGP may be ineffective when administered. Therefore, oncologists should not blindly accept CGP therapeutic recommendations but should make recommendations that lead to optimal therapies after proper verification.

    DOI: 10.21873/invivo.13312

    Web of Science

    Scopus

    PubMed

  • Pembrolizumab Monotherapy<i> Versus</i> Pembrolizumab Plus Chemotherapy in Patients With Head and Neck Squamous Cell Carcinoma

    Matsuo, M; Masuda, M; Yamauchi, M; Taura, M; Hashimoto, K; Kogo, R; Jiromaru, R; Hongo, T; Manako, T; Nakagawa, T

    IN VIVO   37 ( 5 )   2188 - 2196   2023.9   ISSN:0258-851X eISSN:1791-7549

     More details

    Language:English   Publisher:In Vivo  

    Background/Aim: Pembrolizumab monotherapy and pembrolizumab with chemotherapy (combination therapy) are standard treatments for recurrent and metastatic head and neck squamous cell carcinoma (R/M-HNSCC). This study aimed to explore which of the two, pembrolizumab monotherapy or combination therapy is superior for long-term use. Patients and Methods: Participants of the study were 139 patients with histologically confirmed squamous cell carcinoma who had been treated with pembrolizumab monotherapy or combination therapy at the Kyushu University and related facilities. We analysed differences regarding long-term survival rate and adverse events (AEs) between the pembrolizumab monotherapy and combination therapy groups. Results: The overall 2-year progression-free survival and 2-year overall survival were 28.6% and 41.8%, respectively; these results were not significantly different between the two groups. Patients in the monotherapy group with AEs had a significantly better prognosis than those without AEs (in both the monotherapy and combination

    DOI: 10.21873/invivo.13318

    Web of Science

    Scopus

    PubMed

  • HPV Infection in Squamous Cell Carcinoma of the Hypopharynx, Larynx, and Oropharynx With Multisite Involvement

    Kuga, R; Yamamoto, H; Jiromaru, R; Hongo, T; Yasumatsu, R; Matsuo, M; Hashimoto, K; Taniguchi, M; Nakagawa, T; Oda, Y

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY   47 ( 9 )   955 - 966   2023.9   ISSN:0147-5185 eISSN:1532-0979

     More details

    Language:English   Publisher:American Journal of Surgical Pathology  

    The prevalence and prognostic significance of high-risk human papillomavirus (HR-HPV) have been well-established in oropharyngeal squamous cell carcinoma (OPSCC), but not in hypopharyngeal squamous cell carcinoma (HPSCC) or laryngeal squamous cell carcinoma (LSCC). Moreover, HR-HPV infection in squamous cell carcinoma with multisite involvement has not been examined. To clarify these issues, we retrospectively collected 480 invasive tumors from 467 patients with HPSCC, LSCC, or OPSCC, and comprehensively analyzed the detailed tumor localization, transcriptionally active HR-HPV infection by messenger RNA in situ hybridization, and immunohistochemical staining for p16 and Rb. HR-HPV infection was observed in 115/480 tumors (24%). Human papillomavirus (HPV)-positive cases were closely related with p16 positivity and the partial loss pattern of Rb. HR-HPV was detected in 104 of 161 tumors (64.6%) in the pure OPSCC group and only 1 of 253 tumors (0.4%) in the pure HP/LSCC group; the positive case occurred in the vocal cords. In the multisite-involving combined-type squamous cell carcinoma group, HPV infection was observed in 10/40 (25%) cases, and the 10 HPV-positive cases had OPSCC extending to the larynx or hypopharynx. Among high T-stage (T3/T4) cases of pure OPSCC, HPV-positive cases showed a better prognosis (P=0.0144), whereas the HPV-positive combined OPSCC group did not show a better prognosis (P=0.9428), as compared with HPV-negative counterpart. The results suggest that HR-HPV infection in pure HPSCC and LSCC may be extremely rare. HR-HPV infection seems to be present in a substantial proportion of patients with combined OPSCC and HPSCC/LSCC, but it may not improve prognosis at such advanced disease stages. Confirmation of these points awaits future studies with larger cohorts.

    DOI: 10.1097/PAS.0000000000002086

    Web of Science

    Scopus

    PubMed

  • Clinical Management of Early-Stage Hypopharyngeal Squamous Cell Carcinoma: A Single-Institution Clinical Analysis

    Yasumatsu, R; Manako, T; Jiromaru, R; Hashimoto, K; Wakasaki, T; Matsuo, M; Nakagawa, T

    ENT-EAR NOSE & THROAT JOURNAL   102 ( 7 )   NP313 - NP318   2023.7   ISSN:0145-5613 eISSN:1942-7522

     More details

    Language:English   Publisher:Ear, Nose and Throat Journal  

    Objective: Early detection of hypopharyngeal squamous cell carcinoma (SCC) is important for both an improved prognosis and less-invasive treatment. We retrospectively analyzed the detection rates of early hypopharyngeal SCCs according to the evaluation methods and the clinical management of early hypopharyngeal SCCs. Methods: Sixty-eight patients with early hypopharyngeal SCC who were diagnosed were reviewed. Results: The number of early hypopharyngeal cancer patients with asymptomatic or synchronous or metachronous esophageal cancer examined by upper gastrointestinal endoscopy with narrow-band imaging (NBI) was significantly higher than those examined by laryngopharyngeal endoscopy with NBI. The 3-year disease-specific survival rates according to T classification were as follows: Tis, 100%; T1, 100%; T2, 79.8%; and overall, 91.2%, respectively. Conclusions: Early-stage hypopharyngeal SCC can be cured by minimally invasive transoral surgery or radiotherapy. Observation of the pharynx using NBI in patients with a history of head and neck cancer, esophageal cancer, gastric cancer, or pharyngeal discomfort is very important, and routinely examining the pharynx with NBI, even in patients undergoing endoscopy for screening purposes, is recommended.

    DOI: 10.1177/01455613211013084

    Web of Science

    Scopus

    PubMed

  • 喉頭炎症性筋線維芽細胞性腫瘍の3例

    次郎丸 梨那, 松尾 美央子, 山元 英崇, 久我 亮介, 本郷 貴大, 真子 知美, 橋本 和樹, 若崎 高裕, 安松 隆治, 中川 尚志

    頭頸部外科   33 ( 1 )   59 - 65   2023.6   ISSN:1349-581X

     More details

    Language:Japanese   Publisher:(NPO)日本頭頸部外科学会  

    炎症性筋線維芽細胞性腫瘍(Inflammatory myofibroblastic tumor:IMT)は,炎症細胞浸潤と紡錘形細胞の増生を特徴とする稀な中間悪性腫瘍である。3例の喉頭IMTを報告する。1例目は60歳男性で,声帯腫瘍に対し直達喉頭鏡下腫瘍摘出術を施行。2例目は53歳男性で,同様に摘出術を施行した。3例目は40歳男性で,声門下腫瘤の生検のみ施行した。全例FISH法にてALK融合遺伝子を確認しIMTと診断した。治療は外科的切除が第一選択だが,緩徐な増大であることが多く,経過観察に留めることもある。しかし喉頭IMTは,急速増大し窒息に至ることもあり,適切な治療時期の選択が重要である。(著者抄録)

  • Lacrimal Sac Tumors: A Single-institution Experience, Including New Insights

    Wakasaki, T; Yasumatsu, R; Tanabe, M; Yoshikawa, H; Jiromaru, R; Hashimoto, K; Matsuo, M; Fujimura, A; Nakagawa, T

    IN VIVO   37 ( 3 )   1219 - 1225   2023.5   ISSN:0258-851X eISSN:1791-7549

     More details

    Language:English   Publisher:In Vivo  

    Background/Aim: Lacrimal sac tumors are rare tumor types, with a long time interval from disease onset to diagnosis. We aimed to investigate the characteristics and outcomes of patients with lacrimal sac tumors. Patients and Methods: The medical records of 25 patients with lacrimal sac tumors initially treated at the Kyushu university hospital from January 1996 to July 2020 were reviewed. Results: Our analysis included 3 epithelial benign tumors (12.0%) and 22 malignant (88.0%) tumors (squamous cell carcinoma, n=6; adenoid cystic carcinoma, n=2; sebaceous adenocarcinoma, n=2; mucoepidermoid carcinoma, n=1; malignant lymphoma, n=10). The average time from symptom onset to diagnosis was 14.7 months (median=8 months; range=1-96 months). The analysis of patients revealed that lacrimal sac mass (22/25, 88.0%) was the most frequent symptom and a possible tumor marker. Most epithelial benign (n=3) and malignant epithelial (n=12) tumors were treated surgically (14/15, 93.3%). One malignant case was treated with heavy ion beam therapy. Eight patients were treated with postoperative (chemo)radiation therapy because of positive surgical margins (including one unanalyzed case). Local control was ultimately achieved in all but one case. The patient survived for 24 months with immune checkpoint inhibitors and subsequent chemotherapy for local and metastatic recurrence. Conclusion: We report our experience in the diagnosis and treatment of lacrimal sac tumors and analyze the clinical trends in cases involving these tumors. Postoperative radiotherapy and pharmacotherapy, including immune checkpoint inhibitors, may be useful for recurrent cases.

    DOI: 10.21873/invivo.13198

    Web of Science

    Scopus

    PubMed

  • Prognostic factors of nasopharyngeal cancer:An examination of 45 cases in Kyushu University Hospital

    TARUTANI Yu, MATSUO Mioko, HASHIMOTO Kazuki, KOGO Ryunosuke, JIROMARU Rina, HONGO Takahiro, MANAKO Tomomi, NAKAGAWA Takashi

    jibi to rinsho   69 ( 2 )   75 - 81   2023.3   ISSN:04477227 eISSN:21851034

     More details

    Language:Japanese   Publisher:JIBI TO RINSHO KAI  

    <p>In 2018, the new TNM classification (AJCC 8th edition) was introduced. We investigated the prognosis of nasopharyngeal cancer in 45 nasopharyngeal cancer patients who underwent first-line therapy at the Department of Otolaryngology, Head and Neck Surgery, Kyushu University between January 2010 and January 2020. There were 31 male and 14 female patients, ranging in age from 12 to 88 years old, with a median age of 59 years old. Of these, 40 patients with nasopharyngeal squamous cell carcinoma were evaluated for their five-year overall survival (OS) and progression-free survival (PFS) as well as prognostic factors. The 5-year OS rate was 75.5%, and the 5-year PFS rate was 64.3%. As prognostic factors, there were no significant differences in outcome by stage, histological type, and Epstein-Barr virus positivity. In addition, it was considered necessary to further investigate the optimal dose of cisplatin for chemoradiotherapy combined with cisplatin, which is the main treatment for nasopharyngeal cancer.</p>

    DOI: 10.11334/jibi.69.2_75

    CiNii Research

  • 当科における上咽頭癌の予後因子についての検討

    樽谷 勇, 松尾 美央子, 橋本 和樹, 古後 龍之介, 次郎丸 梨那, 本郷 貴大, 真子 知美, 中川 尚志

    耳鼻と臨床   69 ( 2 )   75 - 81   2023.3   ISSN:0447-7227

     More details

    Language:Japanese   Publisher:耳鼻と臨床会  

    上咽頭癌は、ほかの頭頸部癌とは異なる側面を持つことから、予後因子も通常の頭頸部扁平上皮癌とは異なる。2018年にTNM分類が改訂され、上咽頭癌も変更されたため、今回われわれは、新TNM分類を用いて、当科で加療を行った上咽頭癌症例について予後の検討を行った。対象は、2010年1月から2020年1月に九州大学病院耳鼻咽喉・頭頸部外科で一次療法を施行した上咽頭癌45例である。男性31例、女性14例、年齢は12-88歳、中央値59歳であった。これらのうち、上咽頭扁平上皮癌であった40例における5年全生存率(以下OS)、無増悪生存率(PFS)、予後関連因子などについて後方視的に解析を行った。その結果、5年OSは75.5%、5年PFSは64.3%であった。予後関連因子として、Stage別や組織型、Epstein-Barr Virus陽性か否かによる有意差は認められなかった。また、上咽頭癌治療の軸となるシスプラチン併用化学放射線療法については、シスプラチンの至適投与量についてさらなる検討が必要と考えられた。(著者抄録)

  • Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan

    Manako, T; Yasumatsu, R; Nakano, T; Matsuo, M; Takeuchi, T; Taura, M; Tamae, A; Yamauchi, M; Masuda, M; Taguchi, K; Nakagawa, T

    IN VIVO   37 ( 2 )   747 - 755   2023.3   ISSN:0258-851X eISSN:1791-7549

     More details

    Language:English   Publisher:In Vivo  

    Background/Aim: The advent of immune checkpoint inhibitor (ICI) treatment has transformed the treatment of recurrent or metastatic head and neck cancer; however, nasopharyngeal carcinoma (NPC) has not been included in major phase III trials. The clinical outcomes of ICI for NPC in real-world practice remain to be fully elucidated. Patients and Methods: We retrospectively reviewed 23 patients with recurrent or metastatic NPC treated with nivolumab or pembrolizumab at 6 institutions from April 2017 to July 2021 and investigated the correlation of clinicopathological factors and immune-related adverse events with the effects of ICI therapy and the prognosis. Results: The objective response rate was 39.1% and the disease control rate was 78.3%. The median progression-free survival was 16.8 months and overall survival has not been reached. As with other treatment procedures, the efficacy and the prognosis tended to be better in EBER-positive cases than in EBER-negative cases. The rate of significant immune-related adverse events that necessitated discontinuation of treatment was only 4.3%. Conclusion: ICI monotherapy (e.g., nivolumab and pembrolizumab) was effective and tolerable for NPC in a real-world setting.

    DOI: 10.21873/invivo.13137

    Web of Science

    Scopus

    PubMed

  • Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer

    Matsuo, M; Baba, S; Hashimoto, K; Isoda, T; Kitamura, Y; Kogo, R; Jiromaru, R; Hongo, T; Manako, T; Nakagawa, T

    ANTICANCER RESEARCH   43 ( 1 )   183 - 190   2023.1   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publisher:Anticancer Research  

    Background/Aim: Differentiated thyroid cancer (DTC) has a good prognosis, except in the case of patients with radioiodine therapy (RIT)-refractory cancer. However, since DTC is essentially a slowly progressing cancer, it is usually judged to be a DTC with a poor prognosis after multiple RITs and yearly follow-up with echo, computed tomography (CT), and serum thyroglobulin values. This study investigated whether fluorodeoxyglucose-positron emission tomography/CT (FDG PET/CT) combined with initial RIT could identify early-stage patients with poor prognosis. Patients and Methods: We evaluated 100 patients with high-risk DTC who underwent total thyroidectomy and received RIT at our institution. We analyzed the clinical outcomes of patients and 18F-FDG accumulation using univariate and multivariate Cox proportional hazards regression models. Results: The 10-year overall survival (OS) was 87.9%, with no significant difference in OS between 18F-FDG accumulation at pre-total or near-total thyroidectomy (NTT) (p=0.180) and 131I accumulation at initial RIT (p=0.577). However, 18F-FDG positive patients had a significantly worse prognosis than negative patients (p=0.005) at initial RIT. Conclusion: 18F-FDG PET/CT plays an important role in both the diagnosis and prognostic prediction of RIT refractory disease in DTC patients. 18F-FDG PET/CT can be a useful tool particularly at the time of initial RIT since the 18F-FDG accumulation enables the screening of high-risk DTC with poor prognosis at a very early time stage.

    DOI: 10.21873/anticanres.16148

    Web of Science

    Scopus

    PubMed

  • 外切開法による甲状腺手術の際の合併症とその対策

    松尾 美央子

    頭頸部外科   33 ( 2 )   121 - 124   2023   ISSN:1349581X eISSN:1884474X

     More details

    Language:Japanese   Publisher:特定非営利活動法人 日本頭頸部外科学会  

    経頸部切開による甲状腺手術の中でも,良性もしくは被膜外浸潤のない甲状腺癌への甲状腺峡葉切除術は,甲状腺手術の基本である。甲状腺を手術する時のポイントとして,1)反回神経麻痺が発生しにくい Berry靭帯周囲の操作方法,2)上喉頭神経外枝麻痺を低減できる上極の処理方法,3) エナジーデバイスの使用による術後血腫対策が挙げられる。また,甲状腺組織の全摘出が必要な際に,副甲状腺機能を温存できる甲状腺準全摘術は有用な選択肢となる。以上のような合併症への対策をまじえ,経頸部切開法による甲状腺手術手技について述べる。

    DOI: 10.5106/jjshns.33.121

    CiNii Research

  • A case report of three laryngeal inflammatory myofibroblastic tumor

    Jiromaru Rina, Matsuo Mioko, Yamamoto Hidetaka, Kuga Ryosuke, Hongo Takahiro, Manako Tomomi, Hashimoto Kazuki, Wakasaki Takahiro, Yasumatsu Ryuji, Nakagawa Takashi

    JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY   33 ( 1 )   59 - 65   2023   ISSN:1349581X eISSN:1884474X

     More details

    Language:Japanese   Publisher:JAPAN SOCIETY FOR HEAD AND NECK SURGERY  

    Inflammatory myofibroblastic tumor (IMT) is a rare intermediate malignant tumor characterized by inflammatory cell infiltration and proliferation of myofibroblastic and fibroblastic spindle cells. In the present study, we experienced three cases of laryngeal IMT. The first case was a 60-year-old man. He underwent laryngomicrosurgery for a right vocal cord tumor, 7mm in size. One year after the surgery, no evidence of recurrence was seen. The second case was a 53-year-old man with a left vocal cord polyp-like lesion 15mm in diameter with a tendency to enlarge. He underwent laryngomicrosurgery. One year after the surgery, no evidence of recurrence was seen. The third case was a 40-year-old man with IMT diagnosed by a biopsy of a subglottic mass. The case was placed on observation and has remained unaffected for four years. Anaplastic lymphoma kinase (ALK) gene rearrangement was confirmed by fluorescence in situ hybridization in all cases. Preoperative diagnosis of IMT is usually difficult because of the lack of characteristic findings. Surgical resection is the first-line treatment. Although it can cause asphyxia, the increase is generally slow and the choice of timing of treatment needs to be tailored to the pathology. IMT usually has a benign course, but cases with local recurrence or distant metastasis have been reported. In laryngeal IMT, local recurrence was reported in about 20% of cases, and no metastasis was reported. Surgical treatment should be considered in the presence of a hard, enlarging laryngeal mass, with the possibility of IMT.

    DOI: 10.5106/jjshns.33.59

    CiNii Research

  • Utility of FDG PET at the initial radioiodine therapy in differentiated thyroid cancer Reviewed International journal

    Mioko Matsuo, Shingo Baba, Kazuki Hashimoto, Takuro Isoda, Yoshiyuki Kitamura, Ryunosuke Kogo, Rina Jiromaru, Takahiro Hongo, Tomomi Manako and Takashi Nakagawa

    Anticancer Research   2022.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years Invited Reviewed International journal

    in vivo 2022. 36: 1881-1886   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Delayed pharyngocutaneous fstula caused by molecular targeted therapy: a case report Invited Reviewed International journal

    2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Delayed pharyngocutaneous fistula caused by molecular targeted therapy: a case report

    Matsuo, M; Hashimoto, K; Jiromaru, R; Nakagawa, T

    JOURNAL OF MEDICAL CASE REPORTS   16 ( 1 )   383   2022.10   eISSN:1752-1947

     More details

    Language:English   Publisher:Journal of Medical Case Reports  

    Background: Molecular-targeted agents used as a treatment for cancer can cause some rare and serious adverse events such as, delayed wound healing. Depending on the anticancer drug used, temporary withdrawal may be recommended before and after surgery to avoid complications. Once a surgical incision has healed and closed completely, wounds rarely open because of the initiation of molecular targeted therapy several months to years after surgery. Here, we aimed to describe a rare complication of pharyngocutaneous fistula in two patients that was thought to be caused by molecular targeted therapy. Case presentation: Case 1 involved a 64-year-old asian man who developed a delayed pharyngocutaneous fistula 3 months after total laryngectomy for laryngeal cancer. Ramucirumab, a vascular endothelial growth factor receptor inhibitor used for recurrent gastric cancer, was speculated to be involved. Case 2 involved a 71-year-old japanese man who developed a delayed pharyngocutaneous fistula 2 years and 1 month after total pharyngeal laryngectomy for pharyngeal cancer. It was speculated that imatinib, a platelet-derived growth factor receptor alpha inhibitor used for chronic myeloid leukemia, was involved. Conclusions: Although the incidence of late drug-induced anastomotic leakage is very low, when it occurs, it makes oral intake impossible for an extended period and interferes with the appropriate cancer treatment. In this report, we demonstrate the details of these two patients with such a rare complication, which may help accumulate essential data on this topic.

    DOI: 10.1186/s13256-022-03621-2

    Web of Science

    Scopus

    PubMed

  • A case of toothbrush impalement injury penetrating the parapharyngeal space

    MIYAZAKI Takashi, MATSUO Mioko, JIROMARU Rina, HASHIMOTO Kazuki, WAKASAKI Takahiro, YASUMATSU Ryuji, NAKAGAWA Takashi

    jibi to rinsho   68 ( 5 )   346 - 351   2022.9   ISSN:04477227 eISSN:21851034

     More details

    Language:Japanese   Publisher:JIBI TO RINSHO KAI  

    <p>An impalement wound is a form of traumatic injury in which a blunt-tipped, stick-like object pierces the body. Oral and pharyngeal trauma often occurs when a person falls with an instrument in their mouth, and the most common causative instrument is a toothbrush. In this study, we experienced a case of toothbrush impalement injury that penetrated the parapharyngeal space. The patient was a 67-year-old woman who fell while holding a toothbrush in her mouth. The toothbrush penetrated the parapharyngeal space from the left wall of the middle pharynx and reached the left posterior cervical muscles. The internal carotid artery was significantly narrowed by the toothbrush. The toothbrush was removed from the head side of the toothbrush through an external neck incision. There was no bleeding during removal and the wound healed without subsequent infection. When treating patients with pharyngeal impalement wounds, inadvertent removal may result in massive bleeding due to vascular injury or nerve damage. Thus, it is necessary to select an appropriate removal method after observing the anatomical structures by contrast-enhanced CT or angiography. In addition, impalement wounds can cause serious complications, including abscess and other infections, and traumatic internal carotid artery occlusion a few days after injury. It is therefore important to provide appropriate antimicrobial treatment and follow-up of neurological findings.</p>

    DOI: 10.11334/jibi.68.5_346

    CiNii Research

  • 副咽頭間隙を貫いた歯ブラシ杙傷の1例

    宮崎 孝, 松尾 美央子, 次郎丸 梨那, 橋本 和樹, 若崎 高裕, 安松 隆治, 中川 尚志

    耳鼻と臨床   68 ( 5 )   346 - 351   2022.9   ISSN:0447-7227

     More details

    Language:Japanese   Publisher:耳鼻と臨床会  

    杙創は,先端の鈍な棒状の物体が身体に突き刺さる外傷形態の一つである。口腔・咽頭外傷は、器具を口腔内に挿入したまま,転倒した際に発症することが多く、原因器具は、歯ブラシが最多とされる。今回、われわれは、副咽頭間隙を貫通した歯ブラシ杙傷の1例を経験した。症例は67歳の女性で、歯ブラシをくわえたまま転倒した。歯ブラシは中咽頭左側壁から副咽頭間隙を貫通し、左後頸部の筋間に刺入していた。また異物によって内頸動脈は著しく狭窄していた。頸部外切開によって歯ブラシのヘッド側から異物を摘出したが、抜去による出血はなく、その後の感染症の併発もなく治癒した。咽頭杙創の場合、不用意な抜去は血管損傷による大出血や神経障害の可能性があるため、造影CTや血管造影等で正常構造物との関係を把握した上で、適切な抜去法を選択する必要がある。また杙創は受傷後数日経過してから、膿瘍等の感染症や外傷性内頸動脈閉塞症などの重篤な合併症を来すこともあり、適切な抗菌薬治療や神経学的所見の経過観察などを怠らないことが重要であると考えられた。(著者抄録)

  • Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study

    Wakasaki, T; Manako, T; Yasumatsu, R; Hara, H; Toh, S; Masuda, M; Yamauchi, M; Kuratomi, Y; Nishimura, E; Takeuchi, T; Matsuo, M; Jiromaru, R; Hashimoto, K; Komune, N; Nakagawa, T

    PLOS ONE   17 ( 7 )   e0271907   2022.7   ISSN:1932-6203

     More details

    Language:English   Publisher:PLoS ONE  

    Objectives The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration. Materials and methods We retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45). Results The objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B. Conclusion Although PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DIIP, is recommended.

    DOI: 10.1371/journal.pone.0271907

    Web of Science

    Scopus

    PubMed

  • A clinical analysis of oropharyngeal squamous cell carcinoma: a single-institution's experience

    Jiromaru, R; Yasumatsu, R; Yamamoto, H; Kuga, R; Hongo, T; Nakano, T; Manako, T; Hashimoto, K; Wakasaki, T; Matsuo, M; Nakagawa, T

    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY   279 ( 7 )   3717 - 3725   2022.7   ISSN:0937-4477 eISSN:1434-4726

     More details

    Language:English   Publisher:European Archives of Oto-Rhino-Laryngology  

    Purpose: We herein report the treatment outcome of oropharyngeal squamous cell carcinoma (OPSCC) at Kyushu University Hospital, the total number of OPSCC cases, and changes in the proportion of human papilloma virus (HPV)-related carcinomas over time. Method: We performed a retrospective analysis of 237 cases treated for OPSCC at Kyushu University Hospital between 2013 and 2019. We performed HPV-mRNA in situ hybridization and p16 immunohistochemistry. Result: This study included 197 males (82.1%) and 40 females (17.9%). The disease-specific, progression-free and overall survival (OS) were 69%, 62% and 61%, respectively, over the decade-long study period. p16-Immunohistochemistory and highrisk HPV mRNA in situ hybridization were positive in 114 (48.1%) and 105 (44.3%) cases, respectively. The number of HPV-related OPSCC cases increased according to an annual analysis. HPV+ cases had a significantly better prognosis than HPV− cases. In addition, p16+/HPV− cases had a significantly worse prognosis than p16+/HPV+ cases (OS: p = 0.0484). HPV+ OPSCC cases were associated with a younger age (< 60 years old) (p = 0.0429), non-smoker (p = 0.0001), lateral tumor site (< 0.00001), lymphoid metastasis (< 0.0001) and low clinical stage (< 0.0001). Conclusion: The frequency of HPV-related OPSCC cases is increasing in Japan as well as worldwide, and such cases are characterized by no smoking habit, a young age, and a good prognosis. Even in p16+ OPSCC, HPV− cases had a poor prognosis, suggesting the importance of accurate HPV determination. To determine the intensity of treatment for HPV-related and non-related OPSCC, it is necessary to accumulate cases for the accurate HPV determination and comparison of treatment effects.

    DOI: 10.1007/s00405-021-07236-z

    Web of Science

    Scopus

    PubMed

  • Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study

    Nakano, T; YASUMATSU, R; HASHIMOTO, K; KUGA, R; HONGO, T; YAMAMOTO, H; MATSUO, M; WAKASAKI, T; JIROMARU, R; MANAKO, T; TOH, S; MASUDA, M; YAMAUCHI, M; KURATOMI, Y; TAURA, M; TAKEUCHI, T; NAKAGAWA, T

    ANTICANCER RESEARCH   42 ( 7 )   3653 - 3664   2022.7   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publisher:Anticancer Research  

    Background/Aim: This study investigated the effectiveness of pembrolizumab with or without chemotherapy on advanced-stage head and neck cancer (HNC), including nasopharyngeal, sinonasal cavity and external auditory canal cancer, in a real-world setting. Patients and Methods: We retrospectively collected data from 97 HNC patients who were treated with pembrolizumab alone (n=60) or with chemotherapy (n=37), and we investigated the association between clinicopathological findings and treatment response or prognosis. Results: Patients treated with pembrolizumab and chemotherapy had a 1-year overall survival (OS) of 72.8%, objective response rate (ORR) of 48.6%, and serious (≥G3) adverse events (AEs) of 29.7%. Patients treated with pembrolizumab alone had a 1-year OS of 51.9%, ORR of 21.7%, and ≥G3 AEs of 6.7%. Both the ORR and disease control rate (DCR) in the pembrolizumab with chemotherapy group were significantly better than those in the pembrolizumab group (p=0.074 and p=0.00101, respectively). Among patients with distant metastasis, patients on pembrolizumab with chemotherapy achieved significantly better OS than pembrolizumab alone (p=0.0039). Among patients in the pembrolizumab group, both AE-positive and better performance status were associated with longer OS (p=0.011 and p=0.0037, respectively). Conclusion: Our real-world experience reinforces the durability and effectiveness of pembrolizumab for HNC patients. Additionally, our results suggest that pembrolizumab with chemotherapy might be recommended for patients with distant metastasis and no prior treatment. Further studies are needed to determine the optimal treatment strategy for HNC.

    DOI: 10.21873/anticanres.15854

    Web of Science

    Scopus

    PubMed

  • Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years

    Matsuo, M; Yasumatsu, R; Masuda, M; Yamauchi, M; Wakasaki, T; Hashimoto, K; Jiromaru, R; Manako, T; Nakagawa, T

    IN VIVO   36 ( 4 )   1881 - 1886   2022.7   ISSN:0258-851X eISSN:1791-7549

     More details

    Language:English   Publisher:In Vivo  

    Background/Aim: A long-term effect has been confirmed in clinical practice since the introduction of nivolumab for treating various malignant tumors. A similar phenomenon is speculated to occur in head and neck cancer; however, details remain unclear due to the lack of long-term reports. We aimed to investigate the five-year outcomes in long-term responders for over two years, and evaluate the optimal duration of therapy with nivolumab. Patients and Methods: In this retrospective observational study, we analyzed 203 cases of recurrent/metastatic head and neck squamous cell carcinoma (R/MHNSCC), including 33 long-term responders. Results: The median overall survival (OS), 5-year OS, median progression-free survival (PFS), and 5-year PFS values in the 203 cases were 13.1 months, 19.2%, 3.1 months, and 13.2%, respectively. Of the 33 long-term responders, 14 (42.4%) continued using nivolumab for more than 2 years. The remaining 19 patients (57.6%) discontinued nivolumab. The most common reason for discontinuation was severe immune-related adverse events (irAEs) (9 cases; 27.3%); in these 9 cases, the median disease-free survival was 33.2 (range=10.7-44.3) months. Nine patients (21.2%) were considered to have progressive disease (PD) after at least 2 years of administration, and 3 patients (9.1%) requested to discontinue treatment because a complete response (CR) was achieved. Conclusion: This study demonstrated the durable and long-term benefit of nivolumab in R/MHNSCC. In the future, we aim to accumulate real-world data for the establishment of criteria for completion of nivolumab treatment in long-term responders.

    DOI: 10.21873/invivo.12907

    Web of Science

    Scopus

    PubMed

  • 咽頭癌と診断されるも、その後 HIV 感染症合併梅毒と判明した 1 例

    松尾 美央子

    耳鼻と臨床   68 ( 2 )   136 - 139   2022.3   ISSN:04477227 eISSN:21851034

     More details

    Language:Japanese   Publisher:耳鼻と臨床会  

    DOI: 10.11334/jibi.68.2_136

    CiNii Research

  • 特集 頸部リンパ節を見直す 頸部リンパ節腫脹-鑑別の手順- 頸部リンパ節腫脹の画像診断-CT・PET-CT検査-

    松尾 美央子

    JOHNS   38 ( 3 )   275 - 279   2022.3   ISSN:09106820

     More details

    Publisher:東京医学社  

    DOI: 10.24479/ohns.0000000069

    CiNii Research

  • Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy Invited Reviewed International journal

    Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Kazuki Hashimoto, Rina Jiromaru, Tomomi Manako, Takashi Nakagawa

    2022.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 咽頭癌と診断されるも、その後HIV感染症合併梅毒と判明した1例

    松尾 美央子

    耳鼻と臨床   68 ( 2 )   136 - 139   2022.3   ISSN:0447-7227

     More details

    Language:Japanese   Publisher:耳鼻と臨床会  

    症例は62歳男性で、約10日前に出現した舌のしびれと舌根部腫瘤を主訴に、当科を紹介受診となった。舌根部の生検によって得られた病理診断はp16陰性の扁平上皮癌であったことから、中咽頭癌と診断し、加療を予定して治療前採血を施行した。この結果、梅毒とHIVへの重複感染が判明した。その後、性生活を聴取したところ、20代よりsex activityが高く、風俗店などで女性と性交渉を行うことが多かったことが判明、28歳の時に淋病、62歳で性器ヘルペスの既往があった。アモキシシリンの内服を開始したところ、投与開始直後より全身の皮疹の改善に加え舌根部腫瘤も縮小した。再生検による病理診断は炎症性変化のみで癌は否定されたため、初回生検の標本を見直した。その結果、高度炎症による異型上皮であり、癌ではなかったと診断が変更された。現在、アモキシシリンによる梅毒治療は続行しつつ、HIV治療としてHARRT療法も開始されている。

  • Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer

    Nakano, T; Yasumatsu, R; Hashimoto, K; Kuga, R; Hongo, T; Yamamoto, H; Matsuo, M; Wakasaki, T; Jiromaru, R; Manako, T; Toh, S; Masuda, M; Yamauchi, M; Kuratomi, Y; Uryu, H; Nakashima, T; Tamae, A; Tanaka, R; Taura, M; Takeuchi, T; Yoshida, T; Nakagawa, T

    IN VIVO   36 ( 2 )   979 - 984   2022.3   ISSN:0258-851X eISSN:1791-7549

     More details

    Language:English   Publisher:In Vivo  

    Background/Aim: Surgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME). Patients and Methods: We retrospectively collected 19 SGCs from patients treated with the EXTREME regimen. After analyzing EGFR expression and gene copy number gain, we evaluated the correlation between EGFR status and clinicopathological factors and prognosis. Results: EGFR overexpression was detected in 77.8% cases, but not statistically associated with clinicopathological factors or prognosis. EGFR gene copy number gain was detected in 16.7% cases, and statistically positively correlated with lymph node metastasis (p=0.0291). The best overall response was partial response in two cases, stable disease in 15, and progressive disease in one case. The EXTREME regimen was discontinued in all cases. Conclusion: Our results suggest that SGCs are positive for EGFR protein expression but the response rate to the EXTREME regimen was unremarkable.

    DOI: 10.21873/invivo.12790

    Web of Science

    Scopus

    PubMed

  • Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy

    Matsuo, M; Yasumatsu, R; Masuda, M; Toh, S; Wakasaki, T; Hashimoto, K; Jiromaru, R; Manako, T; Nakagawa, T

    IN VIVO   36 ( 2 )   907 - 917   2022.3   ISSN:0258-851X eISSN:1791-7549

     More details

    Language:English   Publisher:In Vivo  

    Background/Aim: The inflammation-based prognostic score (IBPS) has attracted attention recently as a prognostic biomarker for head and neck cancer patients. However, as the IBPS often changes after anticancer drug therapy, its independent prognostic value remains controversial. We aimed to investigate the relationship between the IBPS and prognosis in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with nivolumab, and investigate changes in the IBPS before and after nivolumab treatment. Patients and Methods: Total of 164 patients with RMHNSCC received nivolumab therapy were retrospectively analyzed. Results: Univariate analysis among the 164 patients revealed that the performance status (PS), immune-related adverse event (irAE) status, pre- and post-therapy Glasgow Prognostic Score (GPS), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), platelet-to-lymphocyte ratio (PLR), and post-eosinophil count, were all significant predictors of overall survival (OS) (p<0.05). A multivariate analysis revealed that PS, irAEs, post-GPS, post-NLR, post-CAR, and post-eosinophil count were independent prognostic factors for overall survival. Conclusion: Post-treatment factors were identified as independent prognostic factors for RMHNSCC and can more accurately predict prognosis compared to nivolumab-treated RMHNSCC pre-treatment factors.

    DOI: 10.21873/invivo.12780

    Web of Science

    Scopus

    PubMed

  • Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma

    Hashimoto, K; Yasumatsu, R; Kuga, R; Hongo, T; Yamamoto, H; Matsuo, M; Wakasaki, T; Jiromaru, R; Manako, T; Toh, S; Masuda, M; Yamauchi, M; Kuratomi, Y; Uryu, H; Nakashima, T; Tamae, A; Tanaka, R; Taura, M; Takeuchi, T; Yoshida, T; Nakagawa, T

    ANTICANCER RESEARCH   42 ( 2 )   981 - 989   2022.2   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publisher:Anticancer Research  

    Background/Aim: The efficacy of programmed cell death 1 (PD-1) inhibitor therapy for patients with recurrent and/or metastatic salivary gland carcinoma (R/M SGC) remains unclear. Patients and Methods: We retrospectively analyzed 36 patients with R/M SGC treated with PD-1 inhibitor. The expression of programmed cell death ligand 1 (PD-L1) and mismatch repair (MMR) proteins was also analyzed. Results: The objective response rate (ORR) was 11.1%. The histopathological subtypes of patients who achieved complete response or partial response were salivary duct carcinoma (SDC) in three patients and poorly differentiated carcinoma in one patient, all of whom showed a positive PD-L1 expression. The expression of MMR proteins was not associated with the efficacy of PD-1 inhibitors. Conclusion: Although the efficacy of PD-1 inhibitor therapy in R/M SGC is limited, certain patients may respond and achieve long-term disease control. There is a potential therapeutic effect in SDC patients with positive PD-L1 expression.

    DOI: 10.21873/anticanres.15558

    Web of Science

    Scopus

    PubMed

  • Cancer of the External Auditory Canal with Extensive Osteoradionecrosis of the Skull Base after Re-Irradiation with Particle Beams: A Case Report Invited Reviewed International journal

    Mioko Matsuo Ryuji Yasumatsu Sei Yoshida Rina Jiroumaru Kazuki Hashimoto Takahiro Wakasaki Takashi Nakagawa

    Case Reports in Oncology(Case Rep Oncol )   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab Invited Reviewed International journal

    #Mioko Matsuo, Ryuji Yasumatsu,, Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Kazuki Hashimoto, Ryutaro Uchi, Rina Jiromaru, Kuniaki Sato,Tomomi Manako, Takashi Nakagawa

    Oral Oncology 113 105129 2021   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • レンバチニブ投与中に心筋障害を発症した甲状腺癌例 Invited Reviewed International journal

    松尾美央子、若崎高裕、安松隆治、中川尚志

    耳鼻咽喉科臨床 113;(5) 309-314,2020   2020.8

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 頭頸部癌治療中に様々な血栓症を発症した4症例 Invited Reviewed International journal

    松尾美央子、内龍太郎、田浦政彦、若崎高裕、安松隆治、中川尚志

    頭頸部癌 46(1) 41-45 2020   2020.8

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 甲状腺乳頭癌膵臓転移の1例 Invited Reviewed International journal

    #松尾美央子、内龍太郎、田浦政彦、若崎高裕、安松隆治、中川尚志

    頭頸部癌 113;(5) 309-314 2000   2020.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • A case of nivolumab-induced hypopituitarism in a head and neck cancer patient Invited Reviewed International journal

    Mioko Matsuo, Masahiko Taura, Takahiro Wakasaki, Ryuji Yasumatsu, Takashi Nakagawa

    Otolaryngology Case Reports   14   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Development of active tuberculosis during treatment of head and neck carcinoma: a case series Invited Reviewed International journal

    Mioko Matsuo

    Journal of medical case reports   13   2019.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 原発不明頸部リンパ節転移癌が疑われた濾胞樹状細胞肉腫(Follicular dendritic cell sarcoma:FDCS)の1例 Invited Reviewed International journal

    松尾 美央子

    頭頸部癌   2018.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 初診時遠隔転移を伴う頭頸部扁平上皮癌に対する化学放射線療法の有用性 Invited Reviewed International journal

    松尾美央子、西嶋利光、小池浩次

    頭頸部癌   2017.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 篩骨洞原発 Nuclear protein in testis (NUT) midline carcinoma Invited Reviewed International journal

    松尾美央子、西嶋利光、小池浩次

    日本耳鼻咽喉科学会   2017.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 口腔癌化学放射線治療後に骨髄異型性症候群に至った1例 Invited Reviewed International journal

    松尾美央子、次郎丸梨那

    頭頸部癌   2017.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 頭頸部発生の小細胞癌6症例 Invited Reviewed International journal

    松尾美央子、小池浩次

    頭頸部癌   2017.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Primary mucinous carcinoma with rhabdoid cells of the thyroid gland: a case report Invited Reviewed International journal

    Mioko Matsuo, Masazumi Tuneyoshi, Mari Mine

    Diagnostic Pathology   11   2016.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • レンバチニブが奏功した甲状腺癌2症例の経験 Invited Reviewed International journal

    松尾 美央子

    頭頸部外科   2016.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 頭頸部線様嚢胞癌に対する術後放射線治療と化学療法の有用性の検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、益田宗幸

    耳鼻咽喉科臨床   2016.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • A case of hypopharyngeal cancer with stenosis, perforation, and pyogenic spondylitis development after chemoradiotherapy Invited Reviewed International journal

    Mioko Matsuo, Fumihide Rikimaru, Yuichiro Higaki, Muneyuki Masuda

    International Journal of Surgery Case Reports   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 維持透析中に治療を行った頭頸部癌症例の検討 Invited Reviewed International journal

    松尾美央子、宮崎梨那、小池浩次

    頭頸部癌   2015.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 頭頸部Spindle Cell Carcinomaの6症例 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、益田宗幸

    日本耳鼻咽喉科学会   2015.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 中咽頭癌症例の治療成績とHPV感染の臨床的意義 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、益田宗幸

    頭頸部外科   2014.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 硬口蓋に扁平上皮癌を発症した基底細胞母斑症候群の1症例 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、益田宗幸

    日本耳鼻咽喉学会   2014.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Utility of algorithm-based chemoradioselection in the treatment for advanced hypohparyngeal carcinoma Invited Reviewed International journal

    Muneyuki Masuda, Mioko Matsuo, Takeichiro Aso, Hideyuki Kiyohara, Fumihide Rikimaru, Naonobu Kunitake, Yuichiro Higaki

    Head Neck   2014.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 頭頸部粘膜悪性黒色腫の検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、益田宗幸

    頭頸部癌   2014.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 高齢者頭頸部扁平上皮癌症例の検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、益田宗幸

    頭頸部外科   2013.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 下咽頭癌G-CSF産生腫瘍の1症例 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、益田宗幸

    頭頸部癌   2013.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 頭頸部腺様嚢胞癌72症例の臨床的検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎

    日本耳鼻咽喉科学会   2013.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 喉頭癌T3・T4症例の臨床的検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、冨田吉信

    頭頸部癌   2012.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 自殺企図でTS-1を大量に内服した急性薬物中毒例 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎

    耳鼻咽喉科臨床   2012.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Planned Neck Dissectionの検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、冨田吉信

    頭頸部外科   2011.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 放射線性下顎骨壊死症例の検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、冨田吉信

    日本耳鼻咽喉科学会   2010.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 放射線性喉頭壊死症例の検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、冨田吉信

    頭頸部外科   2010.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 上咽頭癌の予後因子の検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、冨田吉信

    頭頸部癌   2010.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 難治性口腔咽頭潰瘍の5症例 Invited Reviewed International journal

    松尾 美央子

    日本口腔・咽頭科学会   2009.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 中咽頭前壁癌・後壁癌・上壁癌に対する動注化学放射線同時併用療法の検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、檜垣雄一郎、冨田吉信

    頭頸部癌   2009.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 伝染性単核球症を疑った成人Still病 Invited Reviewed International journal

    松尾美央子、井手康介、岡村精一、末松栄一

    耳鼻咽喉科・頭頸部外科   2008.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 早期喉頭癌(Ⅰ期・Ⅱ期)における死因の検討 Invited Reviewed International journal

    松尾美央子、力丸文秀、藤 賢史、檜垣雄一郎、冨田吉信

    喉頭   2005.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

▼display all

Books

  • プラクティス耳鼻咽喉科の臨床1 耳鼻咽喉科日常診療リファレンスブック

    松尾 美央子( Role: Joint author)

    中山書店  2024.5 

     More details

    Responsible for pages:Topics 免疫チェックポイント阻害剤の検査 408-412   Language:Japanese   Book type:Scholarly book

  • JHONS 頸部リンパ節を見直す 頸部リンパ節腫脹の画像診断 CT・PET-CT検査

    松尾 美央子

    2022.1 

     More details

    Language:Japanese  

Presentations

  • 当院における甲状腺癌に対する遺伝子検査の現状

    松尾 美央子、土橋 賢司, 橋本 和樹, 古後 龍之介, 佐藤 方宣, 真子 知美, 中川 尚志

    第36回日本内分泌外科学会  2024.5 

     More details

    Event date: 2024.5

    Language:Japanese  

    Country:Japan  

  • ペンブロリズマブを投与した頭頸部扁平上皮癌患者の長期的予後の検討~単剤群と化学療法併用群の比較~

    松尾 美央子、橋本 和樹、古後 龍之介、佐藤 方宣、真子 知美、中川 尚志

    第33回日本頭頸部外科学会総会ならびに学術講演会  2024.2 

     More details

    Event date: 2024.3

    Language:Japanese  

    Country:Japan  

  • 男女共同参画セッションシンポジウム2 男女共同参画の本質とは?~キャリアアップとワークライフバランス問題~ Invited

    松尾 美央子

    第74回日本気管食道科学会総会ならびに学術講演会  2023.11 

     More details

    Event date: 2024.3

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:福岡   Country:Japan  

  • 切除不能分化型甲状腺癌の治療選択肢 Invited

    松尾 美央子

    甲状腺癌Meet the Expert in 南大阪  2023.7 

     More details

    Event date: 2023.7

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡   Country:Japan  

  • 頭頸部領域悪性腫瘍に対するがんゲノム検査によるPrecision Oncologyの実現率

    松尾 美央子,橋本 和樹,古後 龍之介, 佐藤 方宣, 真子 知美,中川 尚志

    第47回 日本頭頸部癌学会  2023.6 

     More details

    Event date: 2023.6

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大阪   Country:Japan  

  • 手術手技セミナー 7  甲状腺手術 -外切開法による甲状腺手術- Invited

    松尾 美央子

    第124回日本耳鼻咽喉科頭頸部外科学会総会・学術講演会  2023.5 

     More details

    Event date: 2023.5 - 2023.9

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡   Country:Japan  

  • 頭頸部扁平上皮癌患者に対するPembrolizumabの有効性および安全性の検証~多施設共同観察研究~ Invited

    松尾 美央子

    2023.3 

     More details

    Event date: 2023.3

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  • 教育セミナー13「外切開法による甲状腺手術における留意点」 Invited

    松尾 美央子

    第32回日本頭頸部外科学会総会・学術講演会  2023.1 

     More details

    Event date: 2023.1

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  • 分化型甲状腺癌における初回RAI時のFDG-PET/CTの有用性

    松尾美央子、橋本和樹、古後龍之介、次郎丸梨那、本郷貴大、中川尚志

    第32回日本頭頸部外科学会総会・学術講演会  2023.1 

     More details

    Event date: 2023.1

    Language:Japanese  

    Country:Japan  

  • ニボルマブにより 2 年以上の Progression-Free Survival を得ている症例の検討

    松尾 美央子

    第46回 日本頭頸部癌学会  2022.6 

     More details

    Event date: 2022.11

    Language:Japanese  

    Country:Japan  

  • ニボルマブを投与した頭頸部癌症例におけるIBPSの検討

    松尾 美央子, 安松 隆治, 益田 宗幸, 若崎 高弘, 橋本 和樹, 次郎丸 梨那, 真子 知美, 中川 尚志

    日本頭頸部外科学会  2022.3 

     More details

    Event date: 2022.4

    Language:Japanese  

    Country:Japan  

  • 甲状腺癌に対する分子標的薬導入のタイミング

    松尾 美央子

    2021.7 

     More details

    Event date: 2022.2

    Language:Japanese  

    Country:Japan  

  • 粒子線治療から数年後に巨大な瘻孔を来した頭頸部癌の2例

    松尾 美央子

    第122回日本耳鼻咽喉科学会総会・学術講演会  2021.5 

     More details

    Event date: 2022.2

    Language:Japanese  

    Venue:京都   Country:Japan  

  • 頭頸部癌患者に対する抗腫瘍薬投与後に発症した間質性肺炎の11症例

    松尾 美央子

    第45回 日本頭頸部癌学会  2021.6 

     More details

    Event date: 2022.2

    Language:Japanese  

    Country:Japan  

  • 化学放射線療法後再発患者に対する薬物治療の実際 Head & Neck Cancer Expert WEB Meeting

    松尾 美央子

    2020.9 

     More details

    Event date: 2021.5

    Language:Japanese  

    Country:Japan  

  • 2020.1/30 第30回日本頭頸部外科学会総会 学術講演会 頭頸部扁平上皮癌患者に対するニボルマブの臨床効果発現に関与する因子の検討

    @松尾 美央子、 若崎高裕、 安松隆治、 中川尚志

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2014/1/30 第24回日本頭頸部外科学会総会・学術講演会 中咽頭癌症例のHPV感染の有無と治療成績

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2014/6/7 H&L Leaders Meeting in 福岡 Cetuximabと放射線療法の併用

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2014/6/11 第38回日本頭頸部癌学会総会・学術講演会 原発不明頸部リンパ節転移癌の治療成績

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2015/1/29 第25回日本頭頸部外科学会総会・学術講演会 化学放射線治療後に下咽頭穿孔と狭窄および化膿性脊椎炎をおこした1例

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2015/6/5 第39回日本頭頸部癌学会総会・学術講演会,第4回アジア頭頸部癌学会 維持透析患者に合併した頭頸部癌患者の検討

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2015/11/5 甲状腺癌 分子標的治療セミナー 当科におけるレンバチニブの4例の使用経験

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2016.1/28 第26回日本頭頸部外科学会総会・学術講演会 レンバチニブを投与した甲状腺癌4症例

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2016.5/18 第117回日本耳鼻咽喉科学会通常総会・学術講演会 口腔癌化学放射線治療後に骨髄異型性症候群に至った1例

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2016.6/9 第40回日本頭頸部癌学会 頭頸部領域発生の肺外小細胞癌の6症例

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2016.9/23 Tyroid cancer conference in Fukuoka 使用経験から改めて考えるレンバチニブの適応について

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2017.2/2 第27回日本頭頸部外科学会総会・学術講演会 鼻副鼻腔に発生したNUT midline carcinomaの1例

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2017.6/8 第41回日本頭頸部癌学会・学術講演会 初診時遠隔転移を伴う頭頸部扁平上皮癌に対する化学放射線治療の有用性

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2018.1/25 第28回日本頭頸部外科学会総会・学術講演会 喉頭癌治療中に活動性肺結核を発症した1症例

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2018.7/27 レンビマ適正使用セミナー レンバチニブを導入した13例の使用経験から改めて考えること

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2019.1/24第29回日本頭頸部外科学会総会・学術講演会 心臓転移から肺動脈腫瘍塞栓をきたし肺梗塞に至った下咽頭扁平上皮癌の1例

    @松尾 美央子、 若崎高裕、 安松隆治、 中川尚志

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2019.2/15 irAE management seminar 2019 頭頸部癌症例へのNivolumab投与後に発症した間質性肺炎の症例

    @松尾 美央子、 若崎高裕、 安松隆治、 中川尚志

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2019.5/9 第119回日本耳鼻咽喉科学会   レンバチニブが奏効した甲状腺乳頭癌膵臓転移症例の報告

    @松尾 美央子、 若崎高裕、 安松隆治、 中川尚志

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2019.6/14 第43回日本頭頸部癌学会 それぞれ異なる形態の塞栓症を発症した頭頸部癌担癌患者の3症例

    @松尾 美央子、 若崎高裕、 安松隆治、 中川尚志

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2019.6/21 ネクサバール適正使用セミナー TKI製剤使用で重篤な有害事象をおこした症例の報告

    @松尾 美央子、 若崎高裕、 安松隆治、 中川尚志

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2019.9/7 第19回日本内分泌学会九州支部学術集会 アフタヌーンセミナー 甲状腺癌の遺伝子変異と分子標的薬について

    @松尾 美央子

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese  

    Country:Japan  

  • 2014/5/14 第115回日本耳鼻咽喉科学会総会・学術講演会 当科で治療を行ったSpindle Cell Carcinomaの6症例

    @松尾 美央子

    2018.10 

     More details

    Event date: 2018.10 - 2020.7

    Language:Japanese  

    Country:Japan  

  • 高リスク型ヒトパピローマウイルス関連側頭骨扁平上皮癌の臨床病理学的検討

    本郷 貴大, 久我 亮介, 山元 英崇, 次郎丸 梨那, 古後 龍之介, 橋本 和樹, 松尾 美央子, 中川 尚志

    頭頸部癌  2023.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 顎関節に生じたピロリン酸カルシウム結晶沈着症の1例

    菊野 亮栄, 松浦 由布子, 鷺山 幸二, 神谷 武志, 樋田 知之, 山崎 誘三, 石神 康生, 松尾 美央子, 山元 英崇, 藪内 英剛

    Japanese Journal of Radiology  2023.2  (公社)日本医学放射線学会

     More details

    Language:Japanese  

  • 顎義歯装着のための口腔癌再建後のTouch up Surgery

    上薗 健一, 坂本 瑞稀, 吉田 聖, 荻野 洋一郎, 熊丸 渉, 橋本 和樹, 松尾 美央子

    頭頸部癌  2023.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 頸部食道癌の喉頭温存の現状 頸部食道癌における喉頭温存再建手術の現状と未来

    門田 英輝, 吉田 聖, 松尾 美央子, 安松 隆治

    日本気管食道科学会会報  2024.4  (NPO)日本気管食道科学会

     More details

    Language:Japanese  

  • 頭頸部領域悪性腫瘍に対するがんゲノム検査によるPrecision Oncologyの実現率

    松尾 美央子, 橋本 和樹, 古後 龍之介, 真子 知美, 中川 尚志

    頭頸部癌  2023.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 頭頸部癌患者血漿exosome mRNA網羅的解析によるニボルマブの治療効果予測因子の同定 BIO-NEXT

    益田 宗幸, 松尾 美央子, 菅澤 正, 山崎 恵介, 中島 寅彦, 小野 剛治, 上田 勉, 加納 里志, 塚原 清彰, 渡邉 昭仁, 上村 裕和, 門田 伸也, 岩江 信法, 丸尾 貴志, 浅田 行紀, 花井 信広, 佐野 大佑, 藤 賢史

    頭頸部癌  2023.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 遠隔転移を伴う進行下咽頭癌に対して咽頭・喉頭全摘出術を施行した症例の検討

    東原 雅明, 橋本 和樹, 松尾 美央子, 若崎 高裕, 次郎丸 梨那, 門田 英輝, 安松 隆治, 中川 尚志

    日本気管食道科学会会報  2022.4  (NPO)日本気管食道科学会

     More details

    Language:Japanese  

  • 進行口腔癌の下顎骨区域切除における術中迅速骨髄捺印細胞診の意義

    橋本 和樹, 安松 隆治, 松尾 美央子, 若崎 高裕, 次郎丸 梨那, 真子 知美, 山元 英崇, 本郷 貴大, 久我 亮介, 門田 英輝, 吉田 聖, 上薗 健一, 中川 尚志

    頭頸部癌  2022.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 膵癌舌転移の1例

    宮崎 孝, 若崎 高裕, 次郎丸 梨那, 橋本 和樹, 松尾 美央子, 中川 尚志

    口腔・咽頭科  2022.8  日本口腔・咽頭科学会

     More details

    Language:Japanese  

  • 腓骨皮弁による下顎骨再建後の食形態に関係する因子の検討 補綴治療の必要性について

    上薗 健一, 畠山 頌章, 田中 翔一, 阿南 健太郎, 吉田 聖, 荻野 洋一郎, 熊丸 渉, 橋本 和樹, 松尾 美央子, 安松 隆治, 中川 尚志, 門田 英輝

    頭頸部癌  2022.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 簡便かつ安価なHPV関連頭頸部癌同定方法の確立にむけて

    次郎丸 梨那, 安松 隆治, 山元 英崇, 久我 亮介, 本郷 貴大, 真子 知美, 橋本 和樹, 若崎 高裕, 松尾 美央子, 中川 尚志

    頭頸部癌  2022.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 直腸癌中咽頭転移の1例

    東原 雅明, 若崎 高裕, 松尾 美央子, 中川 尚志

    耳鼻咽喉科臨床 補冊  2022.6  耳鼻咽喉科臨床学会

     More details

    Language:Japanese  

  • 男女共同参画セッション:医師として,そして女性としての働き方改革とは? 男女共同参画の本質とは? キャリアアップとワークライフバランス問題

    松尾 美央子

    日本気管食道科学会会報  2024.4  (NPO)日本気管食道科学会

     More details

    Language:Japanese  

  • 当院における甲状腺癌に対する遺伝子検査の現状

    松尾 美央子, 橋本 和樹, 古後 龍之介, 佐藤 方宣, 真子 知美, 中川 尚志

    日本内分泌外科学会雑誌  2024.4  (一社)日本内分泌外科学会

     More details

    Language:Japanese  

  • 当院における喉頭全摘出術後の嗅覚リハビリテーションと嗅覚の改善について

    村上 大輔, 山口 優実, 宮本 雄介, 鈴木 智陽, 菊池 良和, 松尾 美央子, 澤津橋 基広, 中川 尚志

    日本鼻科学会会誌  2022.10  (一社)日本鼻科学会

     More details

    Language:Japanese  

  • 当院における口腔癌の臨床的検討

    次郎丸 梨那, 安松 隆治, 本郷 貴大, 古後 龍之介, 橋本 和樹, 松尾 美央子, 中川 尚志

    頭頸部癌  2023.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 外切開法による甲状腺手術

    松尾 美央子

    日本耳鼻咽喉科頭頸部外科学会会報  2023.4  (一社)日本耳鼻咽喉科頭頸部外科学会

     More details

    Language:Japanese  

  • 喉頭全摘後に気管食道シャントProvoxの挿入を行った27症例の検討

    平野 雄介, 松尾 美央子, 橋本 和樹, 古語 龍之介, 佐藤 方宣, 真子 知美, 中川 尚志

    日本気管食道科学会会報  2024.4  (NPO)日本気管食道科学会

     More details

    Language:Japanese  

  • 再発転移頭頸部扁平上皮癌における血漿ctDNAモニタリングの有用性

    真子 知美, 古後 龍之介, 橋本 和樹, 松尾 美央子, 中川 尚志

    頭頸部癌  2023.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 免疫チェックポイント阻害剤関連口腔咽頭粘膜炎(IMM)の1症例

    原田 里佳, 松尾 美央子, 中川 尚志

    耳鼻咽喉科臨床 補冊  2023.6  耳鼻咽喉科臨床学会

     More details

    Language:Japanese  

  • 下咽頭,喉頭,中咽頭扁平上皮癌におけるHR-HPV感染

    久我 亮介, 山元 英崇, 本郷 貴大, 次郎丸 梨那, 橋本 和樹, 松尾 美央子, 中川 尚志

    頭頸部癌  2023.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • 上部消化管疾患の低侵襲治療 上部消化管瘻孔における内視鏡的PGAシート充填術の有用性

    長末 智寛, 鳥巣 剛弘, 森山 智彦, 梅野 淳嗣, 川崎 啓祐, 藤岡 審, 冬野 雄太, 松野 雄一, 柿添 梢, 進藤 幸治, 松尾 美央子, 北園 孝成

    日本消化器病学会九州支部例会・日本消化器内視鏡学会九州支部例会プログラム・抄録集  2022.12  日本消化器病学会-九州支部

     More details

    Language:Japanese  

  • 上咽頭癌に対する免疫チェックポイント阻害薬の効果について

    真子 知美, 中野 貴史, 松尾 美央子, 竹内 寅之進, 田浦 政彦, 玉江 昭裕, 山内 盛泰, 倉富 勇一郎, 益田 宗幸, 田口 健一, 安松 隆治, 中川 尚志

    日本耳鼻咽喉科頭頸部外科学会会報  2022.4  (一社)日本耳鼻咽喉科頭頸部外科学会

     More details

    Language:Japanese  

  • ルビエールリンパ節転移を有する中咽頭・下咽頭癌症例の臨床検討

    京野 真理, 橋本 和樹, 松尾 美央子, 古後 龍之介, 次郎丸 梨那, 本郷 貴大, 真子 知美, 脇山 浩明, 中川 尚志

    頭頸部癌  2023.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • ニボルマブにより2年以上のProgression-Free Survivalを得ている症例の検討

    松尾 美央子, 橋本 和樹, 次郎丸 梨那, 真子 知美, 中川 尚志, 益田 宗幸, 山内 泰盛

    頭頸部癌  2022.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • コンピュータ支援製造(CAM)法を用いた腓骨皮弁による下顎再建の経験

    田中 翔一, 上薗 健一, 大部 一成, 川野 真太郎, 丸瀬 靖之, 畠山 頌章, 阿南 健太郎, 吉田 聖, 荻野 洋一郎, 橋本 和樹, 松尾 美央子, 安松 隆治, 中川 尚志, 門田 英輝, 中村 誠司

    頭頸部癌  2022.5  (一社)日本頭頸部癌学会

     More details

    Language:Japanese  

  • p16/Rbの組み合わせはHR-HPV感染と転移性LNにおける原発部位の予測に有用である(The p16/Rb combination is helpful to predict HR-HPV infection and the primary site in metastatic LN)

    Kuga Ryosuke, Hashimoto Kazuki, Manako Tomomi, Sato Masanobu, Kogo Ryunosuke, Matsuo Mioko, Nakagawa Takashi

    日本耳鼻咽喉科頭頸部外科学会会報  2024.4  (一社)日本耳鼻咽喉科頭頸部外科学会

     More details

    Language:English  

▼display all

MISC

Professional Memberships

  • 日本喉頭科学会

  • 耳鼻咽喉科臨床学会

  • 日本口腔・咽頭科学会 

  • 日本内分泌甲状腺外科学会

  • 日本臨床腫瘍学会 

  • 日本頭頸部癌学会 

  • 日本頭頸部外科学会

  • 日本耳鼻咽喉科学会

▼display all

Academic Activities

  • Screening of academic papers

    Role(s): Peer review

    2021

     More details

    Type:Peer review 

    Number of peer-reviewed articles in Japanese journals:3

  • 耳鼻と臨床

    2018.4 - 2031.4

     More details

    Type:Academic society, research group, etc. 

Class subject

  • 喉頭

    2022.4 - 2022.9   First semester

  • 上気道

    2022.4 - 2022.9   First semester

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Surgical Clinical Medicine / Otorhinolaryngology

    頭頸部外科